Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must be an adult (18 years) or adolescent (12 to <18years) and weighing 40kg
Participants must have atopic dermatitis that has been present for at least one year
Participants must have 10% body surface area (BSA) of atopic dermatitis involvement
Participants must have had an inadequate response to treatment with topical medications and must not have had treatment with the medications dupilumab, tralokinumab or lebrikizumab
Participants Must Not:
Participant must not have used certain topical atopic dermatitis treatment within 1 week
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Women must not be pregnant, breastfeeding or plan to become pregnant during the study
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo